GALE Antibody | 22-339

GALE Antibody | 22-339 | Gentaur UK, US & Europe Distribution

Host: Rabbit

Reactivity: Human, Mouse, Rat

Homology: N/A

Immunogen: Recombinant fusion protein containing a sequence corresponding to amino acids 129-348 of human GALE (NP_001121093.1) .

Research Area: Cancer, Signal Transduction

Tested Application: WB, IHC, IF

Application: WB: 1:500 - 1:2000
IHC: 1:50 - 1:200
IF: 1:10 - 1:100

Specificiy: N/A

Positive Control 1: SW480

Positive Control 2: SKOV3

Positive Control 3: HepG2

Positive Control 4: U-251MG

Positive Control 5: HeLa

Positive Control 6: Mouse liver

Molecular Weight: Observed: 38kDa

Validation: N/A

Isoform: N/A

Purification: Affinity purification

Clonality: Polyclonal

Clone: N/A

Isotype: IgG

Conjugate: Unconjugated

Physical State: Liquid

Buffer: PBS with 0.02% sodium azide, 50% glycerol, pH7.3.

Concentration: N/A

Storage Condition: Store at -20˚C. Avoid freeze / thaw cycles.

Alternate Name: GALE, SDR1E1

User Note: Optimal dilutions for each application to be determined by the researcher.

BACKGROUND: This gene encodes UDP-galactose-4-epimerase which catalyzes two distinct but analogous reactions: the epimerization of UDP-glucose to UDP-galactose, and the epimerization of UDP-N-acetylglucosamine to UDP-N-acetylgalactosamine. The bifunctional nature of the enzyme has the important metabolic consequence that mutant cells (or individuals) are dependent not only on exogenous galactose, but also on exogenous N-acetylgalactosamine as a necessary precursor for the synthesis of glycoproteins and glycolipids. Mutations in this gene result in epimerase-deficiency galactosemia, also referred to as galactosemia type 3, a disease characterized by liver damage, early-onset cataracts, deafness and mental retardation, with symptoms ranging from mild ('peripheral' form) to severe ('generalized' form) . Multiple alternatively spliced transcripts encoding the same protein have been identified.